SLC5A2 and hydrops fetalis: Such consistency in reducing PASP and mPAP, along with improvements in HF biomarkers, as seen in several RCTs and observational studies, suggests that SGLT2 inhibitors offer robust and replicable benefits across diverse real-world settings.